SCHEMBL5465308

SCHEMBL5465308

CC(C)CCNC(=O)Nc1sc2c(c1C(N)=O)CCCC2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 8/20 0.64
▸ MEN1 O00255 1/20 0.64
▸ CYP1A2 P05177 1/20 0.64
▸ CYP2C19 P33261 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ KDM4E B2RXH2 2/20 0.61
▸ ALDH1A1 P00352 5/20 0.57
▸ HPGD P15428 3/20 0.57
▸ TSHR P16473 3/20 0.57
▸ ALOX15 P16050 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ MAPT P10636 4/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ NPSR1 Q6W5P4 2/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ ANO1 Q5XXA6 1/20 0.56
▸ LMNA P02545 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453309 0.85 PTPN1 (0.46) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL8290423 0.84 ALDH1A1 (0.67) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL5450850 0.84 CFTR (0.58) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL8290448 0.83 ALDH1A1 (0.65) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL5459748 0.82 FLT3 (0.70) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL8289711 0.82 ALDH1A1 (0.70) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL8290436 0.81 FLT3 (0.68) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL5453212 0.80 GAA (0.77) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL8289710 0.80 KDM4E (0.70) FLT3MEN1CYP1A2CYP2C19KMT2A
SCHEMBL3914847 0.79 FLT3 (1.00) FLT3MEN1CYP1A2CYP2C19KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 — — EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 — — WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885MEN1 2891/4885CYP1A2 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback